FDA wants warning on some acetaminophen drugs; Lupin to make Ranexa generic; Shire settles age discrimination lawsuit;

@FiercePharma: Tension rises for pharma in China as court reportedly fines J&J, officials visit Sanofi. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: More bribery allegations in China, these ones against Baxter (and just now surfacing from last year). News | Follow @CarlyHFierce

> CVS Caremark ($CVS) says it will pay a $20 million civil penalty to settle SEC allegations that it made inappropriate public disclosures in 2011 about problems in some units. Story

> Companies that sell prescription acetaminophen will be required to add a warning about the risk of potentially deadly rashes and blistering of the skin, the FDA said Thursday. News

> Mylan ($MYL) has let the markets know that it expects is sales to fall at the low end of its 2013 forecast of $7 billion to $7.4 billion. Report

> Indian generics maker Lupin says the FDA has approved its generic of Gilead Sciences' ($GILD) heart drug, Ranexa. More

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices.com: Covidien watches profits slide after kicking drugs. Article | Follow @FierceMedDev

@MarkHFierce: House Republican freshmen are pressing hard for a vote on a device tax repeal bill. Item | Follow @MarkHFierce

@DamianFierce: Now the Senate is getting in on the push to spare FDA user fees from sequester cuts. Story | Follow @DamianFierce

@MichaelGFierce: Trending on FierceDrugDelivery.com: Swedish team creates 'impossible' record-breaking drug delivery material. Article | Follow @MichaelGFierce

> Smith & Nephew has $1.5B and eyes on M&A. More

> J&J's DePuy, fearing fracture or limb-loss risks, recalls orthopedic implant part. News

> Report: ICU Medical nears sale that could top $1B. Article

Biotech News

@FierceBiotech: Industry Voices: The Zero-Person Biotech Company. Item | Follow @FierceBiotech

@JohnCFierce: Biotech's IPO boom extends its streak through a blistering July. Report | Follow @JohnCFierce

@RyanMFierce: Didn't take the lawyers long to start fishing for angry Optimer shareholders after Cubist buyout announced Tuesday. Release | Follow @RyanMFierce

@EmilyMFierce: NIH team sees diabetes drug as a possible tool for extending life. Story | Follow @EmilyMFierce

> Survey: Americans say cancer should be top priority for medical research. Story

> Stem cell transplants show potential in patients with extremely rare brain disease. More

> Baxter caught up in China bribery scandal. Item

And Finally... Shire ($SHPG) has settled an age discrimination lawsuit by the former head of its Regenerative Medicine unit. Story

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.